DURECT Corporation  

(Public, NASDAQ:DRRX)   Watch this stock  
Find more results for DRRX
2.30
-0.19 (-7.63%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.19 - 2.49
52 week 0.68 - 3.42
Open 2.49
Vol / Avg. 871,330.00/1.21M
Mkt cap 297.73M
P/E     -
Div/yield     -
EPS -0.21
Shares 119.57M
Beta 0.66
Inst. own 41%
Aug 3, 2015
Q2 2015 DURECT Corp Earnings Call - 4:30PM EDT - Add to calendar
Aug 3, 2015
Q2 2015 DURECT Corp Earnings Release - 4:00PM EDT - Add to calendar
Jul 8, 2015
DURECT Corp at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 16, 2015
DURECT Corp Annual Shareholders Meeting (Estimated)
Jun 15, 2015
DURECT Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -101.68% -113.96%
Operating margin -92.60% -108.23%
EBITD margin - -105.14%
Return on average assets -40.72% -48.64%
Return on average equity -114.54% -89.81%
Employees 102 -
CDP Score - -

Address

10240 Bubb Rd
CUPERTINO, CA 95014-4166
United States - Map
+1-408-7771417 (Phone)
+1-408-7773577 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Durect Corporation is a specialty pharmaceutical company. The Company is focused on the development of pharmaceuticals based on its drug delivery technology platforms, chemical entities derived from its Epigenomic Regulator Program, and its engagement in drug development. Its research and development programs fall into one of two categories: Drug Delivery Programs, in which it applies its formulation and technologies to pharmaceutical ingredients, and New Chemical Entities derived from its Epigenomic Regulator Program, in which it discovers and develops molecules. It also manufactures and sells osmotic pumps and biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of seven investigational drug candidates in clinical development: REMOXY (ORADUR-Oxycodone), POSIDUR (SABER-Bupivacaine), ELADUR (TRANSDUR-Bupivacaine), Relday, ORADUR-ADHD, ORADUR-Opioid and SABER-based ophthalmic.

Officers and directors

Felix Theeuwes DSc Chairman, Chief Scientific Officer
Age: 77
Bio & Compensation  - Reuters
James E. Brown DVM President, Chief Executive Officer and Director
Age: 58
Bio & Compensation  - Reuters
Matthew J. Hogan Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance
Age: 58
Bio & Compensation  - Reuters
David R. Hoffmann Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 70
Bio & Compensation  - Reuters
Terrence F. Blaschke M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Armand P. Neukermans Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Jon S. Saxe Independent Director
Age: 78
Bio & Compensation  - Reuters